Purpose: Chemoradiation (CRT) followed by surgery has become the standard of care for the treatment of localized esophageal carcinoma. The rationale for this study was to examine survival outcomes and Quality of Life (QOL) in esophageal carcinoma patients treated with tri-modality therapy in a community cancer centre. Methods and Materials: Patients identified between June 2010 and November 2015 with a diagnosis of adenocarcinoma or squamous cell carcinoma of the esophagus, Stage T1-4N0-3 (AJCC 7th Ed.) and undergoing tri-modality treatment were eligible for this prospective cohort study. QOL (EORTC QLQ C30) and toxicity data (CTCAE v3.0) were collected at baseline, and four weeks, six months, and yearly post-completion of CRT. Results: Sixty patients consented to participate. Data was collected prospectively on 40 patients from diagnosis. Data was collected retrospectively for 20 patients diagnosed between June 2010 to February 2013 when consented at time of follow up, then followed prospectively thereafter. Thirty-three were treated with neoadjuvant CRT with 45-50 Gy in 25 fractions with concurrent 5FU and Cisplatin and 27 patients with 41.4 Gy in 23 fractions, with carboplatin and paclitaxel (CROSS protocol). Median age was 66 years (range: 40-78) with 90% males. Median follow up was 13 months (range 2.3-53). Baseline QOL data was collected in 38 patients in the prospective group. Pathological complete response (pCR) rates were 38% for those receiving CRT with cisplatin/5FU and 22% for those treated with the CROSS protocol. Two-year overall survival (OS) and disease-free survival (DFS) was 68% and 53%, respectively with a median survival of 28 months. No significant differences were seen in DFS or OS between the two treatment regimens (p = 0.95), nor were improved outcomes associated with achieving a pCR (p = 0.17). Median time to recurrence was 16 months, with locoregional recurrence in 17%, distant in 12% and both in 5%. No association was found between baseline global QOL and OS (HR = 0.9, 95% CI: 0.6-1.4) or DFS (HR = 0.8, 95% CI: 0.3-2.4). Additional QOL data will be presented. Conclusions: Survival outcomes in our cohort are in line with those reported in the literature, although pCR rates in our CROSS protocol group were lower compared to the CROSS study, and with short follow up pCR was not significantly associated with better survival outcomes.
Purpose: Radiotherapy (RT) for Hodgkin lymphoma (HL) is associated with late cardiac toxicity (LCT) as a potential complication after treatment. Risk of LCT is known to increase with increasing mean heart dose, however, it is unknown whether evaluating dose to heart substructures, such as the coronary arteries, will provide additional information to predict LCT risk. This study evaluated whether estimating dose to coronary arteries (CA) provided additional explanatory information for LCT compared to estimating whole heart dose alone. Methods and Materials: LCT status of 599 patients receiving mediastinal RT for HL at a tertiary cancer centre between 1988-2003 was determined from medical records and with linkage to a population-based hospitalization dataset. A random sample of 125 of these patients was selected and biomechanical deformable image registration was used to reconstruct 3D heart volumes from 2D imaging using validated methods. Historical RT plans were reconstructed on the 3D CT data sets and the heart and coronary arteries were contoured to estimate dose-volume variables to these structures. Principal Component analysis (PCA) was used to compare the proportion of variation in LCT explained by dose-volume variables to the whole heart versus the heart plus CA. The contribution (loadings) of different parameters (Dmean, Dmax, Dmin, V5, V10, V20, V30) to LCT occurrence was also evaluated. Results: Forty-four cases of LCT were seen, 30 of which were ischemic; other LCT included valvular disease, arrhythmias, pericardial disease, and heart failure. Median follow up was 10.4 years (range: 0.15 -23.8). Median Dmean to the heart, right coronary, left anterior descending, and circumflex arteries were 24.6 Gy, 29.8 Gy, 17.3 Gy, and 27.3 Gy, respectively. Both the PCA of the heart and the heart plus CA had first components that explained > 50% of the variance in LCT, and there was no substantial improvement in explanatory power by adding CA doses in addition to whole heart doses to the PCA. Within components, no single dose-volume parameter explained a large proportion of LCT (i.e. loading > 0.5): in both whole heart, and heart plus CA models, the mean heart dose contributed most to explaining LCT (loading = 0.41 and 0.25, respectively).
Conclusions:
Our results indicate that estimating dose to CA will not add significant explanatory power to predict LCT in HL survivors, compared with documenting dose to the whole heart only. LCT risk in this setting may be mostly predicted by age, sex, comorbidities, and mean heart dose. However, our study may be underpowered to detect a small contribution from dose to the CA that is distinct from whole heart dose.
STEREOTACTIC BODY RADIOTHERAPY FOR LIVER METASTASIS: IMPACT ON SYSTEMIC THERAPY?
Mohammed Aldehaim 1 , Joelle Helou 2 , Hans Chung 2 , Darby Erler 2 , Renee Korol 2 , Melanie Davidson 2 , Liying Zhang 1 , William Chu 2 1 Sunnybrook Health Sciences Centre, Toronto, ON 2 University of Toronto, Toronto, ON Purpose: The management of patients with distant metastasis has historically been systemic therapy (ST). However, that paradigm is shifting to individually personalized care. Stereotactic body radiotherapy (SBRT) enables non-invasive ablation of liver metastases and its use is increasing despite the lack of randomized evidence. We reviewed the outcomes of liver metastases treated with SBRT at our institution, and evaluated the impact of liver SBRT on the treatment algorithm of metastatic patients on ST. Materials and Methods: The records of 112 patients with 149 metastatic liver lesions treated with SBRT between 2011 and 2015 were retrospectively reviewed. Indications for treatment were: oligometastasis (OM) where the objective was to eradicate all sites of disease (≤5 sites); oligoprogression (OP) where only progressing lesions were treated while other sites were stable, and dominant area of progression (DAP) where a growing or symptomatic site was treated even if most or all metastatic deposits were progressing. Lesions were treated with either a 3, 5 or 6 fraction regimen delivered every other day. All patients were evaluable for response based on contrast-enhanced CT obtained at minimum of 4 months after completion of SBRT. Local control (LC), time to liver failure (TLF), time to change ST
